Melane Sampson, Author at BioTuesdays

Executive Moves

Medicus appoints Andrew Smith as COO

Medicus Pharma (NASDAQ: MDCX) has announced the appointment of Andrew Smith as chief operating officer (COO). A seasoned leader in asset management and financial operations with more than three decades of experience, Mr...

June 23, 2025

Executive Moves

Kevin DeGeeter rejoins Ladenburg Thalmann as managing director of biotechnology equity research

Ladenburg Thalmann announced that Kevin DeGeeter has rejoined the firm as a managing director in its equity research department, effective June 2025. In this role, Mr. DeGeeter will lead equity research coverage of...

June 23, 2025

Developments

ArriVent reports encouraging data from firmonertinib monotherapy study in NSCLC

ArriVent BioPharma (NASDAQ: AVBP) announced encouraging additional follow-up proof-of-concept data from its global Phase 1b FURTHER trial of first-line firmonertinib monotherapy in patients with non-small cell lung...

June 23, 2025

Developments

Compass Pathways meets primary endpoint in Phase 3 trial of psilocybin for TRD

Compass Pathways (NASDAQ: CMPS) announced that it has achieved the primary endpoint in the first of two ongoing Phase 3 trials evaluating COMP005 psilocybin for treatment-resistant depression (TRD). The ongoing Phase 3...

June 23, 2025

Developments

Firefly uncovers powerful new method of measuring SCD, MCI, and dementia in Alzheimer’s disease

Firefly Neuroscience (NASDAQ: AIFF) has announced a significant advancement in Alzheimer’s disease research: the company has identified a novel, objective method for measuring and distinguishing between subjective...

June 20, 2025

Developments

PharmaJet and Immuno Cure partner to advance needle-free HIV therapeutic DNA vaccine

Closely held PharmaJet announced that it has signed an agreement with closely held Immuno Cure, a developer of DNA vaccines. Under the agreement, Immuno Cure will use PharmaJet’s Tropis Intradermal (ID) Needle-Free...

June 19, 2025

Executive Moves

Retina specialist Dr. Lloyd Clark joins Annexon

Annexon (NASDAQ: ANNX) announced the appointment of Lloyd Clark, MD, as SVP, ophthalmology strategy and innovation. Dr. Clark brings more than 25 years of experience in treating retinal diseases and advancing novel...

June 19, 2025

Developments

Transgene advances TG4050 to Phase 2 in head and neck cancer trial

Transgene (Euronext Paris: TNG) announced the completion of initial patient screening in the Phase 2 portion of its ongoing Phase 1/2 clinical trial of TG4050—an individualized neoantigen therapeutic...

June 19, 2025

Developments

Telomir’s lead candidate prevents cellular aging in patient-derived cells from children with Progeria

Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data showing that Telomir-1 prevented cellular aging in patient-derived cells from children with progeria—Hutchinson-Gilford Progeria Syndrome (HGPS)—an...

June 18, 2025

Executive Moves

Avalo appoints Dr. Rita Jain to BOD

Avalo Therapeutics (NASDAQ: AVTX) has announced the appointment of Rita Jain, MD, to its board of directors (BOD). To this role, Dr. Jain, a rheumatologist, brings more than two decades of leadership in...

June 18, 2025

Author - Melane Sampson

Medicus appoints Andrew Smith as COO

Kevin DeGeeter rejoins Ladenburg Thalmann as managing director of biotechnology equity research

ArriVent reports encouraging data from firmonertinib monotherapy study in NSCLC

Compass Pathways meets primary endpoint in Phase 3 trial of psilocybin for TRD

Firefly uncovers powerful new method of measuring SCD, MCI, and dementia in Alzheimer’s disease

PharmaJet and Immuno Cure partner to advance needle-free HIV therapeutic DNA vaccine

Retina specialist Dr. Lloyd Clark joins Annexon

Transgene advances TG4050 to Phase 2 in head and neck cancer trial

Telomir’s lead candidate prevents cellular aging in patient-derived cells from children with Progeria

Avalo appoints Dr. Rita Jain to BOD

Subscribe